✦ LIBER ✦

Fatal CMV pneumonitis in a lymphoma patient treated with rituximab

✍ Scribed by Manish Sharma; Jocelyn Moore; Vu Nguyen; Koen Van Besien

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 259 KB
Volume: 84
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.21484

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cerebral nocardiosis in a patient with N

Cerebral nocardiosis in a patient with NHL treated with rituximab

✍ Madappa N. Kundranda; Timothy P. Spiro; Alaa Muslimani; K.V. Gopalakrishna; Mark 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

Radiation recall dermatitis and pneumoni

Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel

✍ Victor G. Schweitzer; Guy J. F. Juillard; Cynthia L. Bajada; Robert G. Parker 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 367 KB 👁 1 views

Dramatic response to single-agent rituxi

Dramatic response to single-agent rituximab in a patient with intravascular lymphoma

✍ Nandagopal Vrindavanam; Mehdi Hamadani; Barbara Steele; Farrukh Awan; Saul Suste 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB 👁 1 views

Primary central nervous system lymphoma

Primary central nervous system lymphoma in a patient treated with Natalizumab

✍ Remy Phan-Ba; Bettina Bisig; Manuel Deprez; Bernard De Prijck; Gael Delrue; Chri 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 308 KB 👁 2 views

Primary central nervous system lymphoma

Primary central nervous system lymphoma in a patient treated with natalizumab

✍ Andreas Schweikert; Marcus Kremer; Florian Ringel; Thomas Liebig; Justus Duyster 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 2 views

## Abstract A 40‐year‐old man with relapsing‐remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th deca

Response of myasthenia gravis to rituxim

Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma

✍ Ajeet Gajra; Neerja Vajpayee; Sara J. Grethlein 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 43 KB 👁 1 views

## Abstract Myasthenia gravis is a B‐cell‐mediated autoimmune neuromuscular disorder characterized by weakness and fatigability of skeletal muscles. The underlying defect is an autoantibody‐mediated attack on the acetylcholine receptors (AchRs) at the neuromuscular junction. Rituximab is a genetica